Extension Study in a Cohort of Adult Patients With COVID-19 Infection
NCT05121740
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
COVID-19 Infection
Interventions
DRUG:
Plitidepsin 1.5 mg / day
DRUG:
Plitidepsin 2.0 mg / day
DRUG:
Plitidepsin 2.5 mg / day
Sponsor
PharmaMar
Collaborators
[object Object]